INTELLIA THERAPEUTICS INC

Intellia insiders’ synchronized equity‑grant purchases show confidence ahead of the lonvo‑z regulatory milestone, signaling potential upside despite current volatility.

Intellia’s insider buying signals confidence amid strong Q4 results and promising CRISPR therapies Lonvo‑Z and MAGNITUDE‑2, hinting at future growth.